product and service
continuous experimentation!
Commercial ā APIs
Active Pharmaceutical Ingredients
| Product Name | Therapeutic Category | Pharmacopoeia | Certificate of Pharmaceutical Product (COPP) | Written Confirmation (W/C) | OP DMF |
|---|---|---|---|---|---|
| Acotiamide Hydrochloride | Gastrointestinal Agent | IH | ā | ā | ā |
| Apixaban | Anti-Coagulant | IH | ā | ā | ā |
| Azelnidipine | Anti-Hypertensive | IH/IP/JP | ā | ā | ā |
| Benfotiamine | Vitamin B1 | IH | ā | ā | ā |
| Benidipine Hydrochloride | Anti-Hypertensive | JP | ā | ā | ā |
| Bilastine | Anti-Histamine | IH/IP | ā | ā | ā |
| Brivaracetam | Anti-Convulsant | IH/IP/EP | ā | ā | ā |
| Citicoline Sodium | Central Stimulant | IH/IP/USP | ā | ā | ā |
| Dapagliflozin Propanediol Monohydrate | Anti-Diabetic | IH/IP/USP | ā | ā | ā |
| Delafloxacin Meglumine | Anti-Bacterial | IH | ā | ā | ā |
| Empagliflozin | Anti-Diabetic | IH | ā | ā | ā |
| Fimasartan Potassium Trihydrate | Anti-Hypertensive | IH | ā | ā | ā |
| Imeglimin Hydrochloride | Anti-Diabetic | IH | ā | ā | ā |
| Luliconazole | Anti-Fungal | IH/IP | ā | ā | ā |
| Mirabegron | Overactive Bladder | IP/EP/BP | ā | ā | ā |
| Oxaceprol | Anti-Inflammatory | IH | ā | ā | ā |
| Prucalopride Succinate | Prokinetic Agent | IH | ā | ā | ā |
| Rivaroxaban | Anti-Coagulant | IH/EP/BP/USP | ā | ā | ā |
| Sacubitril Sodium | Anti-Hypertensive | IH | ā | ā | ā |
| Sacubitril Valsartan | Anti-Hypertensive | IH | ā | ā | ā |
| Teneligliptin Hydrobromide Hydrate | Anti-Diabetic | IH/IP | ā | ā | ā |
| Ursodeoxycholic Acid | Hepatoprotective Agent | IH/EP/BP/IP/USP | ā | ā | ā |
Disclaimer: Products under patent(s) are offered only for R&D purposes and not for commercial sale.
LAB VALIDATED
| Product Name | Therapeutic Category |
|---|---|
| Bempedoic Acid | Lipid Lowering Agent |
| Bisbentiamine | Thiamine Supplement |
| Clascoterone | Anti - Acne |
| Dapagliflozin (Amorphous) | Anti - Diabetic |
| Ibuprofen Arginine | NSAID |
| Isotretinoin | Anti - Acne |
| Norursodeoxycholic Acid | Cholerectic Agent |
| Rifaximin | Anti - Bacterial |
| Teneligliptin Hydrochloride | Anti - Diabetic |
| Vonoprazan Fumarate | Anti - Ulcer / GERD |
| Vortioxetine Hydrobromide | Anti - Depressant |
Disclaimer: Products under patent(s) are offered only for R&D purposes and not for commercial sale.
PRODUCTS UNDER DEVELOPMENT
| Product Name | Therapeutic Category |
|---|---|
| Brexpiprazole | Anti - Psychotic |
| ElafibranorĀ | Liver / Metabolic Disease Agent |
| Ensifentrine | COPD / Respiratory Agent |
| Gefapixant | Chronic Cough Treatment Agent |
| Gepotidacin | Anti - Bacterial |
| Mirogabalin | Neuropathic Pain Agent |
| Resmetirom | Lipid / NASH Treatment Agent |
| Rimegepant Sulfate | Anti - Migraine |
| Upadacitinib | Immunosuppressant |
Disclaimer: Products under patent(s) are offered only for R&D purposes and not for commercial sale.
Intermediates/KSMs List
| Name of Intermediate/KSM | CAS No. | Ā Ā Ā Ā Ā Ā Ā Structure | End Use - API |
| Ethyl-2-Amino 1,3-Thiazole 4-Carboxylate | 5398-36-7 |  Ā | Acotiamide Hydrochloride |
| 2,4,5-Trimethoxy Benzoic Acid | 490-64-2 |  Ā | Acotiamide Hydrochloride |
| Ethyl 2-(2,4,5-trimethoxybenzamido)-1,3-thiazole-4-carboxylate | 185105-98-0 |  Ā | Acotiamide Hydrochloride |
| 1-Benzhydrylazetidin-3-yl 3-Amino-3-iminopropanoate Acetate | 170749-59-4 |  Ā | Azelnidipine |
| 1-(diphenylmethyl)-3-azetidinyl-2-cyanoacetate | 116574-14-2 |  Ā | Azelnidipine |
| Isopropyl 2-(3-nitrobenzylidene)acetoacetate | 39562-25-9 |  Ā | Azelnidipine |
| Ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate | 503614-91-3 |  Ā | Apixaban |
| 2-(4-(2-Chloroacetyl)phenyl)-N-methoxy-N,2-dimethylpropanamide | 1638785-15-5 |  Ā | Bilastine |
| Ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-[3-(isobutyryloxy)azetidin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylate | 442526-91-2 |  Ā | Delafloxacin Meglumine |
| Ethyl 3-oxo-3-(2,4,5-trifluorophenyl) propanoate | 98349-24-7 |  Ā | Delafloxacin Meglumine |
| Benzenepropanoic acid, Ī±-[[(6-amino-3,5-difluoro-2-pyridinyl)amino]methylene]-2,4,5-trifluoro-Ī²-oxo-, ethyl ester | 875712-88-2 |  Ā | Delafloxacin Meglumine |
| Ethyl 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-[3-(2-methyl-1-oxopropoxy)-1-azetidinyl]-4-oxo-3-quinolinecarboxylate | 875712-90-6 |  Ā | Delafloxacin Meglumine |
| 1-(6-Amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 189279-58-1 |  Ā | Delafloxacin Meglumine |
| 2-Butyl-1,6-dihydro-N,N,4-trimethyl-6-oxo-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-5-pyrimidineacetamide | 503155-67-7 |  Ā | Fimasartan |
| 2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H- tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one | 247257-48-3 |  Ā | Fimasartan |
| 2-(2-Butyl-4-hydroxy-6-Methylpyrimidin-5-yl)-N,N- dimethylacetamide (Fima-Pyrimidinamide) | 1315478-13-7 |  Ā | Fimasartan |
| (1R), 2-Chloro-1-(2,4-dichlorophenyl)ethan-1-ol | 114446-57-0 |  Ā | Luliconazole |
| Imidazole 1-acetonitrile Mesylate | 2953074-20-7 |  Ā | Luliconazole |
| (R)-2-Hydroxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide | 521284-19-5 |  Ā | Mirabegron |
| (R)-2-[[2'-(4-nitropheny])-ethyl]amino]-1-phenylethanol monohydrochloride | 521284-21-9 |  Ā | Mirabegron |
| (1R)-2-{[2-(4-Aminophenyl)ethyl]amino}-1-phenylethanol | 391901-45-4 |  Ā | Mirabegron |
| (1R)-2-{[2-(4-Aminophenyl)ethyl]amino}-1-phenylethanol hydrochloride (1:1) | 521284-22-0 |  | Mirabegron |
| 1-(3-methoxypropyl)piperidin-4-amine | 179474-79-4 |  | Prucalopride Succinate |
| 4-amino-5-chloro-2,3-dihydro-1-benzofuran-7-carboxylic acid | 123654-26-2 |  | Prucalopride Succinate |
| 2-{(2R)-2-hydroxy-3-[4-(3-oxomorpholin-4-yl) aniline] propyl}-1- H-isoindole-1,3(2H)-dione | 446292-07-5 |  | Rivaroxaban |
| 1-H isoindole-1,3-(2H)-dione, 2-[[(5S)-2-Oxo-3-[4-(3-oxo-4- morpholinyl)phenyl]-5-oxazolidinyl]methyl]- | 446292-08-6 |  | Rivaroxaban |
| (S)-4-(4-(5-(aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one Hydrochloride | 898543-06-1 |  | Rivaroxaban |
| (S)-glycidyl phthalimide | 161596-47-0 |  | Rivaroxaban |
| ethyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoate hydrochloride | 149690-12-0 |  | Sacubitril Sodium |
| 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione | 2767265-35-8 |  | Clascoterone |
| (R)-3-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)butanenitrile | 118316-12-4 |  | Nor-Ursodeoxycholic acid |
| N,N'-((2Z,2'Z)-disulfanediylbis(5-hydroxypent-2-ene-3,2-diyl))bis(N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamide) (Thaimine Disulfide) | 67-16-3 |  | Bisbentiamine |
| 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid-(Bempedoic acid tech grade) | 738606-46-7 |  | Bempedoic acid |
| 2,2,14,14-tetramethyl-8-oxopentadecanedioic acid | 413624-71-2 |  | Bempedoic acid |
| 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson's Reagent) | 19172-47-5 |  | General Reagent |
Under Development
Ā
| Name of KSM | CAS No. | Structure | End Use - API |
| Tert-butyl -2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoate | 824932-90-3 |  | Elafibranor |
| Tert-butyl (E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoate | 923978-25-0 |  | Elafibranor |
| 1-(Benzo[b]thiophen-4-yl) piperazine hydrochloride | 913614-18-3 |  | Brexpiprazole |
| 7-(4-(4-(Benzo[b]thiophen-4-yl) piperazin-1-yl) butoxy)quinolin-2(1H)-one 4-methylbenzenesulfonate | 2094559-58-5 |  | Brexpiprazole |
| 2-Isopropyl-4-methoxyphenol | 13522-86-6 |  | Gifapixant |
| 2-(2-Isopropyl-4-methoxyphenoxy) acetonitrile | 927872-64-8 |  | Gifapixant |
| Isopropyl 2-(3-nitrobenzylidene)acetoacetate | 865304-71-8 |  | Gifapixant |
| 6-(4-Amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one | 920509-28-0 |  | Resmetirom |
| Ethyl 4-cyano-4-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazinyl)-3-oxobutanoate | 2987937-25-5 |  | Resmetirom |
Services CDMO-CRO
Kimia Biosciences offers Contract Research and Manufacturing and Development Services across the entire value chain of a new chemical entity, which covers from Pre-Clinical to Commercial Phase. We have a strong and dynamic team of scientists functioning from research centers, which are supported by a highly compliant manufacturing footprint with robust multi-product facilities.
As an imminent CRO-CDMO player, we envisageĀ working with India and global innovator pharma companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes.
Robust Supply Chain
1. Comfort to customers with a backward integrated setup that ensures supply assurance of the key intermediates.
2. Scalable infrastructure to counter supply chain oversights going forward
3. Work with clients in flexible, adaptable and customized partnership model for small molecules.
Quality Committed
1. Committed to deliver services with sustain focus on quality, affordable innovation and productivity
One Stop Solution for your Chemical Needs
1. Offering services from mg to metric ton scale
2. We cover the entire life cycle of a new chemical entity at all scales, from pre-clinical and clinical phases to validation and commercial supply, while fully complying with cGMP regulations and standards within WHO GMP, FDA approved facilities.
Environment, Health and Safety
1. We comply with all applicable EHS Legal and other requirements
2. We optimize our resources in a way to prevent and reduce pollution, energy consumption and to increase water conservation.
Ā Services
1. Route Scouting
2. Establishing innovative Route of Synthesis (ROS) from an idea to a sustainable process
3. Process familiarisation, optimisation & development
4. Phase-appropriate process development to ensure successful scale-up and timely product delivery for your clinical trials
5. Analytical method development & validation
6. Phase-appropriate analytical methods using complementing techniques
7. Process safety evaluation
8. Rigorous, data-driven Process Safety evaluation
9. Stability studies
10. Comprehensive range of stability services across time zones
11. Early phase scale-up
Discovery
Kimia Biosciences is a trusted small molecule CRO partner envisaged to help innovator Pharma companies accelerate their drug discovery journey from HIT to IND using creative chemistry supported by high quality , DMPK, toxicology and cGMP scale-up services.
We are known to be responsive, flexible and cost-effective in delivering solutions tailored to suit the program requirements. Our strong and growing scientific team provides a fully-integrated service bringing the collective expertise of various teams together to develop a lead candidate.
- Important Links
KIMIA BIOSCIENCE LIMITED
974, Aggarwal Millennium Tower II,
Netaji Subhash Place, Pitampura,
New Delhi-110 034
+91-11-4706 3600
info@kimiabiosciences.com
sales@kimiabiosciences.com
Kimia Biosciences Ltdā¢ is a leading manufacturer of bulk drugs focused on high-potential therapeutic segments. The company is pursuing an ambitious growth strategy driven by infrastructure expansion and Contract Development & Manufacturing (CDMO) initiatives.